ScripReCode Therapeutics , on track with its plan to take its two lead programs into the clinic this year, announced on 19 September that it raised another $50m in series B venture capital, bringing the ro
ScripRoche Holding AG 's string of brand drug losses in the US is poised to continue with the launch of the first biosimilar version of its ophthalmic blockbuster Lucentis (ranibizumab), potentially in the
Generics BulletinANDA sponsors feel some more tweaking of the assessment process is necessary to speed approval of complex generics, but the US Food and Drug Administration appears more willing to wait for the current
Pink SheetANDA sponsors feel some more tweaking of the assessment process is necessary to speed approval of complex generics, but the US Food and Drug Administration appears more willing to wait for the current